Phases, active trials: Phase 1: 54, Phase 2: 58, Phase 3: 70, Other: 55
AbbVie's clinical pipeline is anchored by two powerful commercial franchises: hematology/oncology (Imbruvica/ibrutinib, Venclexta/venetoclax) and immunology (Skyrizi/risankizumab, Rinvoq/upadacitinib) as Humira biosimilar competition has accelerated revenue transition. In hematology, Venclexta's BCL-2 inhibition platform is expanding into AML, MDS, and combinations beyond CLL/SLL. Imbruvica successor programs (zanubrutinib and next-gen BTK degraders) continue generating new trials. In immunology, Skyrizi (IL-23p19) and Rinvoq (JAK1) are rapidly gaining label expansions across psoriatic arthritis, IBD, Crohn's disease, and atopic dermatitis. AbbVie's 2020 Allergan acquisition added the aesthetics pipeline and Botox franchise.
- Hematology (BCL-2, BTK, AML)
- Immunology (IL-23, JAK1)
- Oncology combinations (venetoclax-based)
- IBD / GI inflammation
- Dermatology
- Venclexta (venetoclax): BCL-2 inhibitor, CLL/AML
- Imbruvica (ibrutinib): BTK inhibitor, B-cell malignancies
- Skyrizi (risankizumab): IL-23p19, psoriasis/Crohn's/UC
- Rinvoq (upadacitinib): JAK1 inhibitor, arthritis/IBD/atopic
- ABBV-CLS-484: SIRPα/CD47 axis, solid tumors
- Teliso-V (telisotuzumab vedotin): c-MET ADC, NSCLC
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space… NCT05210803 | Primary completion moved at least 3 years 3 months later Primary endpoint reworded | Enrolling by Invitation |
26 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD NCT05407636 | Oct 2026 · Estimated | Phase 3 |
21 more on the Completions page. See the calendar →
Monitor the AbbVie pipeline daily
Get a daily digest when AbbVie registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Crohn's Disease | 13 |
| Multiple Myeloma | 13 |
| Healthy Volunteer | 11 |
| Ulcerative Colitis | 11 |
| Atopic Dermatitis | 10 |
| Migraine | 9 |
| Acute Myeloid Leukemia | 7 |
| Chronic Lymphocytic Leukemia | 7 |
AbbVie's venetoclax combination trials are the most closely watched in hematology, any new BCL-2 combination registered by AbbVie (e.g., with hypomethylating agents, CDK inhibitors, or immunotherapy) signals new standard-of-care potential in AML or CLL. Companies developing competing hematology assets must monitor this pipeline.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to AbbVie's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: AbbVie may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your AbbVie pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid… NCT06972446 | Recruiting | Interventions modified | 2026-10-09 |
| A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of… NCT06820463 | Recruiting | Trial sites expanded: 75 → 78 locations | 2026-10-09 |
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult… NCT07592273 | Recruiting | Trial sites expanded: 34 → 37 locations | 2026-10-09 |
| Study to Assess Participant Satisfaction After Jawline and Neck Treatment NCT07794891 | Recruiting | Start date changed from estimate of Sep 4, 2026 to Sep 9, 2026 | 2026-10-09 |
| A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the… NCT07222709 | Active, Not Recruiting | Completion pushed from Sep 2026 to Nov 2026 | 2026-10-09 |
Each trial page shows every change DataLookout has recorded for that trial.